GCP-2 Inhibitors
Granulocyte chemotactic protein-2 (GCP-2) serves as a pivotal chemokine within the immune system, specifically orchestrating the mobilization and recruitment of neutrophils to areas of infection or injury. By binding to specific receptors on neutrophils, GCP-2 facilitates their directed movement across the endothelial barrier and towards the sites requiring immediate immune intervention. This chemotactic guidance is crucial for initiating an effective inflammatory response, ensuring that neutrophils, as primary defenders against bacterial infections, are efficiently deployed to neutralize pathogens and facilitate tissue repair. The regulation of GCP-2, therefore, is not merely a matter of immune activation but also involves intricate mechanisms of suppression and inhibition to prevent overreaction and the potential for inflammatory damage that could result from an unmoderated neutrophil response. The balance maintained by GCP-2 activity underscores its significance in immune homeostasis, where its function must be precisely modulated to reflect the current physiological needs of the body.
The inhibition of GCP-2, a process essential for the resolution of inflammation and the prevention of chronic inflammatory states, involves a complex interplay of biochemical pathways that serve to downregulate its expression or block its activity. Inhibition strategies may target the upstream signaling pathways that regulate GCP-2 production, such as those mediated by NF-κB, MAPK, and PI3K/Akt, which are critical for the transcriptional and post-transcriptional control of chemokine expression. Additionally, the modulation of cellular processes that impact the stability, secretion, or receptor binding affinity of GCP-2 can also serve as effective means to suppress its chemotactic function. This involves not only the direct inhibition of the chemokine itself but also the broader regulation of the inflammatory milieu that dictates GCP-2 levels. By influencing the cellular and molecular mechanisms that govern the synthesis, release, and activity of GCP-2, it is possible to mitigate the extent and duration of neutrophil recruitment, thereby aiding in the resolution of inflammation and the restoration of tissue integrity. Such regulatory mechanisms are vital for maintaining the delicate equilibrium between effective immune defense and the prevention of immune-mediated damage, highlighting the critical nature of GCP-2 inhibition in immune system modulation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that blocks the kinase activity of p38 MAPK. This inhibition can reduce cytokine production and inflammatory responses, potentially suppressing GCP-2 expression or activity indirectly by affecting signaling pathways that regulate inflammation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that blocks phosphatidylinositol 3-kinase activity, leading to decreased Akt phosphorylation. Reduced PI3K/Akt signaling can lower inflammatory responses and potentially decrease GCP-2 activity by limiting the cellular processes that drive its expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that prevents the activation of the MAPK/ERK pathway. By inhibiting ERK phosphorylation, it may indirectly reduce GCP-2 activity by altering transcriptional responses involved in inflammation and chemokine expression. | ||||||
Apocynin | 498-02-2 | sc-203321 sc-203321A sc-203321B sc-203321C | 1 g 10 g 100 g 500 g | $27.00 $68.00 $116.00 $360.00 | 74 | |
Apocynin inhibits NADPH oxidase, reducing reactive oxygen species (ROS) production. Lower ROS levels can decrease NF-κB activation, potentially reducing GCP-2 expression by affecting a key signaling pathway involved in its regulation. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 inhibits NF-κB activation by blocking IκBα phosphorylation. This action can indirectly inhibit GCP-2 by reducing the transcriptional activation of genes involved in inflammation and immune responses. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that blocks the activity of c-Jun N-terminal kinases. This inhibition can modulate inflammatory gene expression, potentially leading to reduced GCP-2 activity by affecting signaling pathways that regulate chemokine expression. | ||||||
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
AG490 (Tyrphostin B42) is a JAK2 inhibitor that blocks the JAK/STAT signaling pathway. Inhibiting this pathway can lead to decreased inflammatory cytokine production, potentially reducing GCP-2 expression or activity by altering critical signaling involved in immune responses. | ||||||
Wiskostatin | 253449-04-6 | sc-204399 sc-204399A sc-204399B sc-204399C | 1 mg 5 mg 25 mg 50 mg | $49.00 $124.00 $441.00 $828.00 | 4 | |
Wiskostatin inhibits GLUT1, reducing glucose uptake in cells. This action might indirectly suppress GCP-2 by affecting cellular metabolism and energy availability, which are essential for the production and release of inflammatory mediators. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $91.00 $139.00 $374.00 | 36 | |
Dexamethasone is a glucocorticoid that inhibits NF-κB, reducing the expression of pro-inflammatory cytokines. This broad anti-inflammatory effect can indirectly suppress GCP-2 expression by modulating the overall inflammatory milieu. | ||||||
IKK-2 Inhibitor IV | 507475-17-4 | sc-203083 | 500 µg | $133.00 | 12 | |
IKK-2 Inhibitor IV prevents NF-κB activation. By inhibiting this key signaling molecule, it can reduce inflammatory responses and potentially decrease GCP-2 activity by limiting transcriptional activation of inflammation-related genes. | ||||||